Ertiprotafib is a phosphotyrosine (pTyr) monocarboxylic acid mimetic developed by Wyeth and the first PTP1B inhibitor to be tested in clinical trials for the treatment of diabetes [36]. This evidence concerns the gene PTPN1 and diabetes mellitus.